Olatoyosi Odenike to Drug Administration Schedule
This is a "connection" page, showing publications Olatoyosi Odenike has written about Drug Administration Schedule.
Connection Strength
0.112
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.055
-
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. N Engl J Med. 2015 Sep 03; 373(10):920-8.
Score: 0.029
-
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005 Jun 01; 11(11):4176-81.
Score: 0.014
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.014